Author

Heiner Wedemeyer 1

1 Medizinische Hochschule Hannover,Hannover,Germany

99.7% SUSTAINED VIROLOGIC RESPONSE RATE IN 369 HCV GENOTYPE 1B-INFECTED PATIENTS TREATED WITH LABEL-RECOMMENDED REGIMEN OF OMBITASVIR/PARITAPREVIR/R AND DASABUVIR WITH OR WITHOUT RIBAVIRIN

Jean-François Dufour, Heiner Wedemeyer, David E. Bernstein, Massimo Colombo, Manuel Romero-Gomez, Nancy Reau, Roger Trinh, Wangang Xie, Jeffrey Enejosa, Daniel E. Cohen, Marisol Martinez, Ira M. Jacobson

Chronic hepatitis B and delta

Heiner Wedemeyer

Direct acting antivirals and HCC: There is no risk!

Heiner Wedemeyer

HBV-INFECTION IN GERMANY ? COSTS IN A REAL-LIFE SETTING

Hans Becker, Jona T. Stahmeyer, Anna Lena Orlemann, Christian Krauth, Michael Manns, Heiner Wedemeyer

HDV: Towards individualised treatment

Heiner Wedemeyer

Hepatitis D

Heiner Wedemeyer

Hepatitis Delta: Current treatment and novel concepts

Heiner Wedemeyer

Hepatitis E in 2021

Heiner Wedemeyer

SAFETY COMPARISON OF 12- AND 24-WEEK TREATMENTS IN HCV GENOTYPE 1-INFECTED PATIENTS WITH CIRRHOSIS: RESULTS FROM TURQUOISE-II

Heiner Wedemeyer, Xavier Forns, Antonio Craxi, Paul Kwo, Stefan Bourgeois, Michael Bennett, Stephen Ryder, Dominique Larrey, David Mutimer, Sandra Lovell, Manal Abunimeh, Marcos Pedrosa, Roger Trinh

SIX WEEKS OF SOFOSBUVIR/LEDIPASVIR TREATMENT OF  ACUTE HEPATITIS C VIRUS GENOTYPE 1 MONOINFECTION: FINAL RESULTS OF THE THE GERMAN HEPNET ACUTE HCV IV STUDY

Katja Deterding, Christoph D Spinner, Eckart Schott, Tania M Welzel, Guido Gerken, Hartwig Klinker, Ulrich Spengler, Johannes Wiegand, Julian Schulze zur Wiesch, Anita Pathil, Markus Cornberg, Andreas Umgelter, Caroline Zöllner, Stefan Zeuzem, Armin Papkalla, Kristina Weber, Svenja Hardtke, Heiko von der Leyen, Armin Koch

Item 1 - 10 / 22
1
2 3